Relevant Articles

While diabetes research is ongoing and ever-evolving, these papers will provide you with insight into the role of STARLIX (nateglinide) and mealtime glucose fluctuations.

Brunzell JD, Robertson RP, Lerner RL, et al. Relationships between fasting plasma glucose levels and insulin secretions during intravenous glucose tolerance tests. J Clin Endocrinol Metab .1976;42:222-229.

Ceriello, A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes. 2005;54:1-7.

Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev. 2000;16:125-132.

Del Prato S, Heine RJ, Keilson L, Guitard C, Shen SG, Emmons RP. Treatment of patients over 64 years of age with type 2 diabetes. Diabetes Care. 2003;26:2075-2080.

Fonseca V, Grunberger G, Gupta S, et al. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. Diabetes Care. 2003;26:1685-1690.

Gavin JR III.The importance of postprandial hyperglycaemia. Int J Clin Pract Suppl. 1999;107:14-17.

Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA. Two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care. 2005;28:2093-2099.

Hollander PA, Schwartz SL, Gatlin MR, et al. Importance of early insulin secretion: Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care. 2001;24:983-988.

Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23:1660-1665.

Horton ES, Foley JE, Shen SG, Baron MA. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes. Current Medical Research and Opinions. 2004;6:883-889.

Jensen CC, Cnop M, Hull R, Fujimoto WY, Kahn S, American Diabetes Association GENNID Study Group. ß-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes. 2002;51:2170-2178.

Koro C, Bowlin SJ, Bourgeios N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes. Diabetes Care. 2004;27:17-20.

Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care. 2003;26:881-885.

Ward WK, Beard JC, Halter JB, Pfeifer MA, Porte D Jr. Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care. 1984;7:491-502.

Weyer C, Bogardus C, Mott DM, Pratley RE.The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104:787-794.

Important Safety Information

STARLIX is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

STARLIX is contraindicated in patients with a known hypersensitivity to the drug or its inactive ingredients, in patients with type 1 diabetes, or in patients with diabetic ketoacidosis. Patients with ketoacidosis should be treated with insulin.

All oral blood glucose lowering drugs that are absorbed systemically are capable of producing hypoglycemia. Patients should be advised to take STARLIX 1 to 30 minutes prior to eating a meal and to skip the dose if the meal is missed.

STARLIX should be used with caution in patients with moderate to severe liver disease because such patients have not been studied.

The most common adverse events associated with STARLIX vs placebo were upper respiratory infection (10.5% vs 8.1%), back pain (4.0% vs 3.7%), flu symptoms (3.6% vs 2.6%), dizziness (3.6% vs 2.2%), arthropathy (3.3% vs 2.2%), and diarrhea (3.2% vs 3.1%).

Please see the full prescribing information.